Featured Research

from universities, journals, and other organizations

Chemotherapy Appears To Delay Cancer Recurrence Following Surgery For Pancreatic Cancer

Date:
January 17, 2007
Source:
JAMA and Archives Journals
Summary:
Use of the drug gemcitabine for chemotherapy significantly delays the recurrence of cancer, compared to no chemotherapy, for patients following pancreatic cancer surgery, according to a study in the January 17 issue of JAMA.

Use of the drug gemcitabine for chemotherapy significantly delays the recurrence of cancer, compared to no chemotherapy, for patients following pancreatic cancer surgery, according to a study in the January 17 issue of JAMA.

With an estimated 232,000 new cases per year, pancreatic cancer is among the most common malignancies worldwide. It is also one of the most lethal cancers, with a mortality incidence ratio of 98 percent, according to background information in the article. Pancreatic cancer is the fourth leading cause of death from cancer in the U.S., with 32,300 deaths estimated in 2006. Surgery is the only curative treatment option for this type of cancer, though the prognosis still often remains poor. Therefore, surgery alone is an inadequate approach to achieve long-term disease control in patients with resectable (surgically remove a part of an organ) pancreatic cancer.

Helmut Oettle, M.D., Ph.D., of Charite School of Medicine, Campus Virchow-Klinikum, Berlin, Germany, and colleagues conducted a study (CONKO-001) comparing use of the drug gemcitabine with no anticancer drug therapy in 368 patients who had undergone complete resection of pancreatic cancer. The study was conducted from July 1988 to December 2004 at 88 oncology centers in Germany and Austria. Patients received chemotherapy with gemcitabine (n = 179), or no chemotherapy (observation; [control, n = 175]).

With a median (midpoint) follow-up of about 4.5 years, recurrent cancer developed in 74.3 percent in the gemcitabine group and 92 percent in the control group. The estimated median disease-free survival was 13.4 months in the gemcitabine group compared with 6.9 months in the control group. Estimated disease-free survival at 3 and 5 years was 23.5 percent and 16.5 percent in the gemcitabine group, and 7.5 percent and 5.5 percent in the control group, respectively. There was no difference in overall survival between the gemcitabine group and the control group.

"The results of CONKO-001 indicates that adjuvant treatment with gemcitabine in the dose and schedule used has minimal toxicity, does not compromise quality of life, and offers a good, and currently perhaps the best, chance for prolonged disease-free survival in patients undergoing [certain types of] resection for pancreatic cancer," the authors conclude.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Cite This Page:

JAMA and Archives Journals. "Chemotherapy Appears To Delay Cancer Recurrence Following Surgery For Pancreatic Cancer." ScienceDaily. ScienceDaily, 17 January 2007. <www.sciencedaily.com/releases/2007/01/070116205541.htm>.
JAMA and Archives Journals. (2007, January 17). Chemotherapy Appears To Delay Cancer Recurrence Following Surgery For Pancreatic Cancer. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2007/01/070116205541.htm
JAMA and Archives Journals. "Chemotherapy Appears To Delay Cancer Recurrence Following Surgery For Pancreatic Cancer." ScienceDaily. www.sciencedaily.com/releases/2007/01/070116205541.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Microneedle Patch Promises Painless Pricks

Microneedle Patch Promises Painless Pricks

Reuters - Innovations Video Online (Oct. 18, 2014) Researchers at The National University of Singapore have invented a new microneedle patch that could offer a faster and less painful delivery of drugs such as insulin and painkillers. Video provided by Reuters
Powered by NewsLook.com
Raw: Nurse Nina Pham Arrives in Maryland

Raw: Nurse Nina Pham Arrives in Maryland

AP (Oct. 17, 2014) The first nurse to be diagnosed with Ebola at a Dallas hospital walked down the stairs of an executive jet into an ambulance at an airport in Frederick, Maryland, on Thursday. Pham will be treated at the National Institutes of Health. (Oct. 16) Video provided by AP
Powered by NewsLook.com
Raw: Cruise Ship Returns to US Over Ebola Fears

Raw: Cruise Ship Returns to US Over Ebola Fears

AP (Oct. 17, 2014) A Caribbean cruise ship carrying a Dallas health care worker who is being monitored for signs of the Ebola virus is heading back to Texas, US, after being refused permission to dock in Cozumel, Mexico. (Oct. 17) Video provided by AP
Powered by NewsLook.com
Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

AFP (Oct. 17, 2014) All four suspected Ebola cases admitted to hospitals in Spain on Thursday have tested negative for the deadly virus in a first round of tests, the government said Friday. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins